Results 71 to 80 of about 37,380,162 (289)

Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor–specific inhibitor

Tumor Biology, 2017
Vascular endothelial growth factor receptor-2 is a dynamic target for therapeutic intervention in various types of cancers. This study was aimed to explore the anti-angiogenic activity of a novel vascular endothelial growth factor receptor–specific ...
Appu Rathinavelu, Khalid Alhazzani, Sivanesan Dhandayuthapani, Thanigaivelan Kanagasabai   +3 more
doaj   +1 more source

Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer

Molecular Medicine Reports, 2009
Vascular endothelial growth factor A (VEGF-A) is a key regulator of angiogenesis that binds to the receptors VEGFR-1 and VEGFR-2. It is well known that VEGF-A levels are increased in colorectal cancer (CRC) tissue compared to normal colorectal tissue, but little is known regarding the expression of the VEGFR-1 and -2 receptors.
Hansen, Torben F., Garm Spindler, Karen-Lise, Olsen, Dorte A, Andersen, Rikke F., Lindebjerg, Jan, Brandslund, Ivan, Jakobsen, Anders, Lorentzen, Karen Axelgaard   +7 more
openaire   +5 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Role of Pentacyclic Triterpenoids in Chemoprevention and Anticancer Treatment: An Overview on Targets and Underling Mechanisms

Journal of Pharmacopuncture, 2019
DNA: Deoxyribonucleic acid, BRCA1: Breast cancer gene 1, BRCA2: Breast cancer gene 2,WHO: World Health Organization, Nrf2: Nuclear factor erythroid 2 [NF-E2]-related factor 2 , NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells, MDR ...
Mahavir H. Ghante, Prasad G. Jamkhande
doaj   +1 more source

Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus. [PDF]

, 2010
Kaposi's sarcoma (KS) is the most common cancer among HIV-positive patients. Histogenetic origin of KS has long been elusive due to a mixed expression of both blood and lymphatic endothelial markers in KS tumor cells.
Kafka, Darren, Koh, Chester J., Aguilar Berenice, Yoo, Jaehyuk, Hong Young-Kwon, Hong, Young-Kwon, Lee, Sunju, Choi, Inho, Yoo Jaehyuk, Haas, Jürgen G., Kang Jinjoo, Lee Ha Neul, Swapnika Ramu, Kang, Jinjoo, Young-Kwon Hong, Juneyong Lee, Ramu, Swapnika, Darren Kafka, Lee, Juneyong, Kafka Darren, Lee Sunju, Choi Inho, Juergen Haas, Haas, Juergen, Lee Juneyong, Sunju Lee, Inho Choi, Ha Neul Lee, Haas Juergen, Aguilar, Berenice, Chester J. Koh, Jinjoo Kang, Chester J Koh, Jaehyuk Yoo, Koh Chester J., Berenice Aguilar, Ramu Swapnika, Lee, Ha Neul   +37 more
core   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Analysis of the mechanisms of resistance to Epidermal growth factor receptor inhibitors and development of multiple targeted strategies [PDF]

, 2008
Background. Primary and acquired resistance to selective Epidermal growth factor receptor (EGFR) inhibitors remains the most significant obstacle to the success of these targeted agents in cancer therapy.
Rosa, Roberta
core   +1 more source

Mechanisms of vascular morphogenesis and stabilization by VEGF dose [PDF]

, 2014
VEGF is the master regulator of angiogenesis and the most investigated factor in therapeutic angiogenesis approaches to induce the growth of new vessels that could restore oxygen and nutrients supply in tissues affected by ischemia.
Groppa, Elena
core   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier [PDF]

British Journal of Ophthalmology, 2006
Pathological neovascularisation within the normally avascular cornea is a serious event that can interfere with normal vision. Upregulation of vascular endothelial growth factor (VEGF) has been associated with neovascularisation in the eye, suggesting that maintaining low levels of VEGF is important for corneal avascularity and intact vision.
Balamurali K, Ambati, Emory, Patterson, Pooja, Jani, Crystal, Jenkins, Eric, Higgins, Nirbhai, Singh, Tushar, Suthar, Nehali, Vira, Kimberly, Smith, Ruth, Caldwell   +9 more
openaire   +2 more sources